Xebra Brands Ltd. (“Xebra”) (CSE: XBRA) (OTC: XBRAF) (FSE: 9YC), a cannabis company, is pleased to announce that it has commenced formal cannabis cultivation in the Netherlands, including THC varietals.
As 1 of only 5 companies to be selected by the Dutch government to participate in trial medicinal cannabis cultivation, Xebra is endeavoring to be awarded 1 of 2 licenses, with a contract for up to 6 years, providing for revenues of up to US$79 million (€70.5 million), to co-supply all pharma-grade cannabis to be sold in the Netherlands.
Cultivation in the Netherlands is conducted in Xebra’s indoor facility. Xebra’s specific genetic varieties are characterized by high production, compact flowers of excellent quality and fine tasting terpene profiles, with a growth cycle of 12-16 weeks.
Xebra’s Director of Operations in the Netherlands, Harry von Duijne, is an experienced cannabis horticulture expert with more than two decades of practicing horticulture. He had a leading role at Bedrocan NL® from 2014 and 2017, where he was responsible for managing every aspect of operations of a state-of-the-art cannabis facility, from construction through cultivation and processing, quality management, and GMP certification. Bedrocan® produces medicinal-grade cannabis under contract for the Dutch Ministry of Health as the only licensed producer in the Netherlands, and for many years was the only licenced producer in all of Europe.
